Bank of China International released a research report saying that the 26-year reports of listed companies in the pharmaceutical sector have already been disclosed. Overall, the overall growth of the pharmaceutical industry is resilient, and structural repairs continue to be interpreted. The bank believes that the normalization of industry collection, fee control, and compliance and rectification has weakened marginally. At the same time, policy support for innovation continues to be strengthened, and a trend of industry profit restoration has been established. The bank continues to be optimistic about the long-term development of the pharmaceutical industry and maintains a stronger rating than the market.

Bank of China International released a research report saying that the 26-year reports of listed companies in the pharmaceutical sector have already been disclosed. Overall, the overall growth of the pharmaceutical industry is resilient, and structural repairs continue to be interpreted. The bank believes that the normalization of industry collection, fee control, and compliance and rectification has weakened marginally. At the same time, policy support for innovation continues to be strengthened, and a trend of industry profit restoration has been established. The bank continues to be optimistic about the long-term development of the pharmaceutical industry and maintains a stronger rating than the market.